ROSEN, NATIONAL TRIAL LAWYERS, Encourages Corcept Therapeutics Incorporated to Secure Counsel Before Important Deadline in Securities Class Action - CORT

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Corcept Therapeutics Incorporated during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Corcept common stock between October 31, 2024, and December 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 21, 2026 [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Case Background - The lawsuit alleges that Corcept misrepresented the strength of clinical trials for relacorilant, claiming it was a strong support for their New Drug Application (NDA) to the FDA, while the FDA had raised concerns about the clinical evidence [5]. - The defendants indicated confidence in the NDA approval process, stating that relacorilant was "approaching approval," despite known risks that it might not be approved [5].